{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-029671","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.309043+00:00","generated_at":"2026-06-04T22:59:22.843287+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Atossa Therapeutics appoints breast cancer specialist Dr. Tessa Cigler to board","bullets":["Dr. Cigler is a medical oncologist and clinical investigator at Weill Cornell Breast Center.","She will serve as Class II director until 2026 annual meeting and on Nominating and Governance Committee.","Appointment effective immediately; compensation follows standard non-employee director terms.","Company's (Z)-endoxifen program has four Phase 2 trials; two expected to readout in H2 2024.","Dr. Cigler holds M.D. from Duke, M.P.H. from Harvard, and extensive breast cancer clinical trial experience."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-029671","json":"https://secwatch.observer/filing/0000950170-24-029671.json","markdown":"https://secwatch.observer/filing/0000950170-24-029671.md","text":"https://secwatch.observer/filing/0000950170-24-029671.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000095017024029671/0000950170-24-029671-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000095017024029671/atos-20240309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:59:22.843287+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c42fb057ae","claim":"Tessa Cigler was appointed as Class II Director at ATOSSA THERAPEUTICS, INC..","evidence_excerpt":"On March 9, 2024, the Board of Directors (the “Board”) of Atossa Therapeutics, Inc. (the “Company”) expanded its size and appointed Dr. Tessa Cigler, M.D., M.P.H. as a Class II director to hold office until the 2026 Annual Meeting of Stockholders and until her successor shall have been duly elected and qualified, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000095017024029671/0000950170-24-029671-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}